论文部分内容阅读
目的:观察多西紫杉醇联合顺铂治疗晚期乳腺癌的疗效及不良反应。方法:晚期乳腺癌患者45例,予多西紫杉醇联合顺铂方案化疗:多西紫杉醇40mg/m2,静脉点滴,1h以上,第1天、第8天;顺铂25mg/m2,静脉点滴,第1～3天,并予适当水化。每3周为1个周期。2周期后评价疗效,有效者化疗4周期以上。结果:45例中完全缓解7例,部分缓解19例,稳定13例,疾病进展6例,总有效率为57.7%(26/45)。不良反应主要为骨髓抑制、脱发、消化道反应,但均可耐受,无化疗相关死亡。结论:多西紫杉醇为主的联合化疗方案治疗晚期乳腺癌疗效较好,不良反应可耐受。
Objective: To observe the efficacy and adverse reactions of docetaxel combined with cisplatin in the treatment of advanced breast cancer. Methods: Forty-five patients with advanced breast cancer were treated with docetaxel plus cisplatin chemotherapy: docetaxel 40mg / m2, intravenous drip for more than 1h, on day 1 and 8; cisplatin 25mg / m2, intravenous drip, 1 to 3 days, and appropriate hydration. Every 3 weeks for a period. 2 cycles after the evaluation of efficacy, effective chemotherapy for more than 4 cycles. Results: Of the 45 patients, 7 were completely relieved, 19 were partially relieved, 13 were stable, and 6 were disease progression. The total effective rate was 57.7% (26/45). Adverse reactions mainly for bone marrow suppression, hair loss, gastrointestinal reactions, but are tolerable, no chemotherapy-related deaths. Conclusion: Docetaxel-based combination chemotherapy regimen is effective in treating advanced breast cancer, and adverse reactions are tolerable.